All lobbying filings

BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for NOVARTIS · Multinational biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · $90,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 1

HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 1

Health Issues

Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.